|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118110 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-02 14:51:09 |
|
注册时间: Date of Registration: |
2026-02-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
"雾镜成像+点阵离焦技术”视力管理镜片在青少年儿童近视防控中的应用 |
|
Public title: |
Application of "Fog Mirror Imaging +Dot Matrix Defocus Technology" Vision Management Lenses in Myopia Control for Adolescents and Children |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
"雾镜成像=点阵离焦技术”视力管理镜片在青少年儿童近视防控中的应用 |
|
Scientific title: |
Application of "Fog Mirror Imaging = Dot Matrix Defocus Technology" Vision Management Lenses in Myopia Control for Adolescents and Children |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李影 |
研究负责人: |
李影 |
|
Applicant: |
Li Ying |
Study leader: |
Li Ying |
|
申请注册联系人电话: Applicant telephone: |
+86 151 6213 0727 |
研究负责人电话:
Study leader's |
+86 151 6213 0727 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liying20220318@163.com |
研究负责人电子邮件: Study leader's E-mail: |
liying20220318@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省徐州市泉山区中山北路19号 |
研究负责人通讯地址: |
江苏省徐州市泉山区中山北路19号 |
|
Applicant address: |
No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province |
Study leader's address: |
No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
221002 |
研究负责人邮政编码: Study leader's postcode: |
221002 |
|
申请人所在单位: |
徐州医科大学附属徐州市立医院 |
||
|
Applicant's institution: |
Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University |
||
|
研究负责人所在单位: |
徐州医科大学附属徐州市立医院 |
||
|
Affiliation of the Leader: |
Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
xyyll(2005)-XJSFX-275 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
徐州市第一人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First People's Hospital of Xuzhou |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-20 00:00:00 | ||
|
伦理委员会联系人: |
张颖 |
||
|
Contact Name of the ethic committee: |
Zhang Ying |
||
|
伦理委员会联系地址: |
江苏省徐州市泉山区中山北路19号 |
||
|
Contact Address of the ethic committee: |
No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 516 6816 7579 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
徐州市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First People's Hospital of Xuzhou |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省徐州市泉山区中山北路19号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海京鸿光学有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Jinghong Optics Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
近视 |
||||||||||||||||||||||
|
Target disease: |
myopia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过一项随机、对照、非劣效性临床试验,评估双控镜片对比新乐学(DIMS)镜片在延缓青少年近视进展方面的有效性和安全性。主要目的是验证配戴双控镜片12个月后,在控制眼轴增长方面是否非劣于DIMS镜片。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aimed to evaluate the efficacy and safety of dual-control lenses in slowing the progression of myopia in adolescents by conducting a randomized, controlled, non-inferiority clinical trial, in comparison with Defocus Incorporated Multiple Segments (DIMS) lenses. The primary objective was to verify whether dual-control lenses are non-inferior to DIMS lenses in controlling axial length elongation after 12 months of wear. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄6至12岁,性别不限; 2.屈光状态符合下述条件: (1)睫状肌麻痹后电脑验光检测双眼等效球光度在 -0.50D~-6.00D之间(包括-0.50D和-6.00D); (2)睫状肌麻痹后电脑验光检测双眼散光均不超过2.0D; (3)睫状肌麻痹后电脑验光检测双眼屈光参差小于2.00D; 3.双眼眼内压正常(大于等于10mmHg,小于等于21mmHg); 4.任一眼最佳矫正远视力优于或等于0.8; 5.双眼无弱视或其他任何眼球病理性改变; 6.患者本人清楚了解,自愿参加该项研究,并由本人及家长/监护人签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age 6 to 12 years, any gender; 2. Refractive status meets the following conditions: (1) After cycloplegia, computer-based refraction shows both eyes with an equivalent spherical diopter between -0.50D and -6.00D (including -0.50D and -6.00D); (2) After cycloplegia, computer-based refraction shows astigmatism in both eyes not exceeding 2.0D; (3) After cycloplegia, computer-based refraction shows anisometropia in both eyes less than 2.00D; 3. Intraocular pressure in both eyes is normal (greater than or equal to 10 mmHg, less than or equal to 21 mmHg); 4. Best-corrected distance visual acuity in either eye is equal to or better than 0.8; 5. No amblyopia or any other pathological changes in either eye; 6. The patient fully understands and voluntarily participates in this study, and the informed consent form is signed by both the patient and the parent/guardian. |
||||||||||||||||||||||
|
排除标准: |
1.有任何可能与近视发展相关或影响眼屈光状态的眼部或全身疾病(如先天性白内障,早产儿视网膜病变,马凡氏综合征,糖尿病等)或疾病; 2.存在显性斜视或明显双眼视功能异常; 3.不愿配合访视者; 4.研究者判断患者不适合入选的其它情况; 5.正在参加其它可能对本研究有影响的临床试验,或者三个月内使用过其他近视防控手段,如低浓度阿托品或者角膜塑形镜,红光治疗等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Any ocular or systemic diseases that may be related to the development of myopia or affect refractive status (such as congenital cataract, retinopathy of prematurity, Marfan syndrome, diabetes, etc.); 2. Presence of manifest strabismus or obvious binocular visual function abnormalities; 3. Unwillingness to cooperate with visits; 4. Other situations where the researcher determines the patient is not suitable for inclusion; 5. Currently participating in other clinical trials that may affect this study, or having used other myopia control methods within the past three months, such as low-concentration atropine, orthokeratology lenses, red light therapy, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-04 00:00:00至 To 2027-05-07 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-02-04 00:00:00 至 To 2027-05-07 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由东南大学公共卫生学院阮增良副教授用R软件产生随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Associate Professor Zengliang Ruan, from the School of Public Health, Southeast University, was responsible for generating the random sequence with R software. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对受试者,检查人员,医生设盲 |
|
Blinding: |
Blinding for subjects, examiners, and doctors |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |